TIVC Earnings

TIVC reported its earnings on 2025-11-14, showcasing a revenue of 146.00K against an estimate of , resulting in a 0% surprise. The EPS was -1.97, surpassing the expected 0 by 0%. The stock experienced a -21.31% price change on the earnings day and a -16.23% change over the next five days, reflecting market reactions to the results.

Following TIVC's earnings announcement on 2025-11-14, the stock price moved by -21.31% on the day of the release. Over the subsequent five days, it saw a -16.23% change. Historically, TIVC's stock price tends to shift by an average of 22.87% in the 10 days leading up to earnings and -7.31% in the 10 days following, providing insight into potential market.

For , analysts estimate TIVC's annual revenue to reach , while the EPS is projected at . These estimates reflect recent revisions, with revenue estimates revised downward by -54.49% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between TIVC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for were revised downward by -54.49%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TIVC's stock price typically moves by 22.87% in the 10 days before its earnings and -7.31% in the 10 days after. For the upcoming earnings, analysts expect an EPS of and revenue of .

The earnings call highlights significant challenges: declining revenue due to reduced marketing, increased operating expenses, and substantial net losses. Despite efforts to pivot towards immunotherapeutics, financial constraints and regulatory hurdles pose risks. The cash position is weak, raising concerns about sustainability. While gross margins improved, the lack of positive catalysts like new partnerships or strong guidance suggests a negative outlook. The absence of clarity in management responses during the Q&A further exacerbates uncertainties, likely leading to a negative stock price reaction.